Following are the preferred responses for the Patient Management Problem in this Continuum issue. The case, questions, and answer options are repeated, and the preferred response is given, followed by an explanation and a reference with which you may seek more specific information. You are encouraged to review the responses and explanations carefully to evaluate your general understanding of the material. The comment and references included with each question are intended to encourage independent study.
To obtain CME credits for this activity, subscribers must complete this Patient Management Problem online at www.aan.com/continuum/cme. Upon completion of the Patient Management Problem, participants may earn up to 2 AMA PRA Category 1 Credits TM . Participants have up to 3 years from the date of publication to earn CME credits. No CME will be awarded for this issue after April 30, 2019.
They now find he repeats questions and stories multiple times within a few minutes, is confused when attempting to complete projects at home or pay the bills, and has accused family members of stealing his wallet. He has not experienced any hallucinations. He was recently laid off from his job as a welder. He drives and has had no accidents or tickets in the past 3 years. He smokes 10 cigarettes and drinks two beers per day. He has no significant past medical history and takes no medications. b 1. Given the patient's history, what is the most likely working diagnosis?
A. Alzheimer disease B . autoimmune encephalopathy C. dementia with Lewy bodies D. frontotemporal dementia E . vascular cognitive impairment
The preferred response is A (Alzheimer disease). The patient's initial forgetfulness as described by the family is suggestive of amnestic mild cognitive impairment. Over time, his symptoms progressed to indicate that his memory impairments and deficits in executive functioning (difficulty completing projects) and navigation impacted his daily functioning, consistent with progression to dementia. The gradual onset and progression of deficits in short-term memory and navigation are most commonly associated with Alzheimer disease. 1 The preferred response is A (impaired episodic memory, mild anomia, mild deficits on executive function tests). Patients with Alzheimer disease demonstrate early deficits in episodic memory, often manifested by impaired recall of recently learned information. 1 In the early stages of the disease, encoding and consolidation are impaired while retrieval is relatively preserved. Executive function tasks are often impaired early on in Alzheimer disease, and some patients may demonstrate mild anomia. Category fluency is typically impaired while letter fluency may be preserved. Deficits on visuospatial tasks are common. Grammar is typically preserved in patients with Alzheimer disease, including in the logopenic aphasia variant of primary progressive aphasia typically associated with Alzheimer disease pathology. 1 Single-word comprehension is preserved in Alzheimer disease, but is a classic deficit in semantic dementia. is administered. The patient shows difficulties learning a list of words, with just 5 out of 10 recalled immediately after three trials and, following a delay, he recalls only 2 out of 10 words. He is able to copy a circle but makes mistakes when drawing a cube. He follows all commands and names only 8 out of 12 items correctly. He is oriented to the year but not the month or day of the week.
b 4. Which of the following additional measures or historical features would be most important to obtain in this patient?
A. history of exposure to ticks B . retrieval of patient's driving record from the department of motor vehicles/ministry of transportation C. screening for depression and other neuropsychiatric symptoms D. screening for risk factors for syphilis E . vaccination history
The preferred response is C (screening for depression and other neuropsychiatric symptoms). Assessment of a patient with cognitive complaints should include screening for depression and other neuropsychiatric symptoms, which can be associated with deficits in attention, concentration, and working memory. 1 Patients with impairments in frontal lobe functions or memory may have impaired insight or recollection of these symptoms; thus, collection of collateral history from a knowledgeable informant is essential. A review of neuropsychiatric symptoms including agitation, wandering, impulsivity, delusions, hallucinations, anxiety, depression, and insomnia should be reviewed at each visit as these symptoms may inform the diagnosis and often impact quality of life for patients and caregivers and thus require management when possible. 2 Delusions of theft and infidelity are common in patients with Alzheimer disease, and anxiety and depression are common in patients with Alzheimer disease and dementia with Lewy bodies. Additionally, screening for safety-related behaviors such as wandering, use of the stove, presence of guns, or use of other dangerous equipment or tools in the home is indicated at each visit. Physicians are not required to obtain official driving records but confirmation of the patients' driving history within the past 5 years, including difficulties with navigation, accidents, or tickets from a reliable informant, is critical. b 6. Which is the most appropriate imaging test to order at this time?
A. amyloid PET B . CT angiography of head and neck C. CT scan of the brain D. fluorodeoxyglucose positron emission tomography (FDG-PET) of the brain E . MRI scan of the brain
The preferred answer is E (MRI scan of the brain). A structural imaging study is indicated for patients presenting with cognitive deficits to rule out a structural etiology such as a tumor or normal pressure hydrocephalus. MRI is preferred, as white matter lesions and microhemorrhages such as those seen in cerebral amyloid angiopathy, either of which may contribute to cognitive impairment, may be better visualized on MRI. 1, 2 For patients unable to undergo MRI, CT imaging is a reasonable substitute. FDG-PET and amyloid PET may help specifically to differentiate Alzheimer disease from frontotemporal dementia but are not routinely indicated in the diagnostic workup of patients presenting with cognitive impairment. There is no specific role for vascular imaging in the initial workup of cognitive impairment. The preferred answer is A (a cholinesterase inhibitor). The cholinesterase inhibitors donepezil, galantamine, and rivastigmine are typically indicated for symptomatic treatment of cognitive impairment in mild to moderate Alzheimer disease. Donepezil and the high-dose rivastigmine patch (13.3 mg every 24 hours) are approved by the US Food and Drug Administration (FDA) for use in severe Alzheimer disease. These medications have been associated with a modest improvement in cognition in a portion of patients with Alzheimer disease. While there have been case reports published suggesting benefit of coconut oil in Alzheimer disease, controlled trials are ongoing, and there is insufficient evidence to date to recommend this as therapy. Trials of vitamin E and ginkgo biloba have failed to show a benefit in Alzheimer disease. Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has also been approved for use in moderate to severe Alzheimer disease. While memantine appears safe as monotherapy or when added to a cholinesterase inhibitor, evidence of a modest benefit is equivocal in moderate to severe Alzheimer disease 1 and meta-analysis suggests there is not a benefit in patients with mild Alzheimer disease. 2 Thus, some recent guidelines support the use of memantine in moderate and severe Alzheimer disease, and others suggest there is insufficient evidence to support or refute use of memantine in moderate to severe Alzheimer disease. 3 b 8. When counseling the patient and family prior to prescribing a cholinesterase inhibitor, which of the following should be discussed as the most common side effect?
The preferred answer is B (gastrointestinal symptoms). On average, the cholinesterase inhibitors are associated with an approximate 20% incidence of gastrointestinal side effects including nausea, with approximately 5% of patients experiencing more severe nausea, vomiting, or diarrhea. 1 A less common but more serious adverse reaction to the cholinesterase inhibitors is bradycardia, which can be life threatening. 2 Thus, measurement of pulse and assessment of cardiac symptoms is indicated before initiation. Less common and less serious side effects of this class include vivid dreams, including nightmares, and persistent rhinorrhea. Other possible side effects due to cholinergic effects include seizures, worsening of urinary obstruction in patients with prostatic hyperplasia or urinary outlet obstruction, or exacerbation of asthma. As many patients will not show a favorable response to this class of medications, response to treatment should be assessed after a few months. 3 If no favorable response is observed, discontinuation is recommended, and a trial of an alternate agent in the class can be considered. b 9. Which of the following factors best predicts a patient's driving abilities?
A. caregiver's rating of patient's driving as safe B . history of crashes in the past 5 years C. lack of reduction of patient's driving mileage or situational avoidance D. neuropsychological testing scores E . patient's self-reported driving abilities
The preferred answer is B (history of crashes in the past 5 years). There is level C evidence that a history of crashes in the past 5 years or traffic citations in the past 3 years are associated with an increased risk of future crashes. 1 Caregivers' ratings of patients' driving as unsafe is a predictor of unsafe driving, but the opposite, caregivers' judgment of patients' driving as safe, has not been found to be reliably associated with safe driving performance. A reduction in driving mileage or situational avoidance has been associated with increased risk of unsafe driving, but a lack of reduction or avoidance has not. The presence of impulsive or aggressive personality characteristics has been associated with unsafe driving risk. While neuropsychological testing generally has not been highly predictive of driving risk, an MMSE score or 24 or less may be somewhat useful in identifying patients possibly at increased risk of unsafe driving. 1 Studies of driving in patients with dementia have tended to collapse the groups across all causes of dementia and, thus, have weighted the results toward patients with Alzheimer disease. The few studies conducted in patients with frontotemporal dementia consistently indicate that the risk of unsafe driving is high even in early stages of disease, while there are no studies specifically in patients with dementia with Lewy bodies. At the next visit the patient's spouse and adult children ask if his illness could be hereditary and if they and the patient can be tested for genetic risks. The patient's father had ''dementia'' with onset around age 55. The family recalls that he became angry and stopped recognizing family members. He went into a nursing home and died around age 70. A paternal uncle had depression and also developed dementia in his late fifties. The patient's mother lived to age 86 and died of a myocardial infarction.
b 10. To address the family's question about heritability, what is the next appropriate step? A. reassurance that familial early-onset Alzheimer disease is rare B . referral of the patient and family for genetic counseling C. screening of the family members for early-onset Alzheimer disease gene mutations D. testing for apolipoprotein E (APOE) genotype E . testing of the patient for presenilin 1 (PSEN1), amyloid-" precursor protein (APP), and presenilin 2 (PSEN2) mutations
The preferred answer is B (referral of the patient and family for genetic counseling). A referral for genetic counseling is recommended for symptomatic testing for patients with possible familial early-onset Alzheimer disease and is essential for individuals considering predictive testing. The patient's presentation with probable Alzheimer disease prior to age 60 and likely history of early-onset dementia in his father raise the possibility of an autosomal dominant early-onset familial Alzheimer disease. Autosomal dominant mutations are a rare cause of Alzheimer disease overall; however, in kindreds with three family members across three generations affected before age 60, the probability of identifying an autosomal mutation is approximately 86%. 1 The most common genetic mutation associated with familial early-onset Alzheimer disease is PSEN1, followed by mutations in APP. APOE4 status is associated with a higher risk of developing Alzheimer disease but the presence is not diagnostic and, thus, symptomatic and predictive genetic testing of APOE genotype is not recommended. At the next visit 6 months later, the patient's spouse appears rather distressed and notes that he has become more dependent and requires near complete supervision at home due to wandering tendencies. She is tearful and reports poor sleep as she is fearful he may fall or wander when he awakens in the middle of the night.
b 12. Which of the following represent important management approaches for these behaviors?
A. prescription of an antidepressant for the caregiver B . prescription of a sleep aid for the caregiver C. prescription of a sleep medication for the patient D. prescription of quetiapine for wandering behavior E . referral of the patient to a day program The preferred response is E (referral of the patient to a day program). Caregivers of patients with dementia are at high risk of depression, caregiver burnout, and medical problems. As the patient's dementia advances, maintaining options for caregiver respite is critical for the well-being of the patient and caregiver. Referrals to local day care programs for patients with dementia, Alzheimer society for social work and caregiver support groups, and other community organizations for care relief are essential for caregivers. 1 Prescription sleep aids are associated with only a mean increase of 15 minutes of increased sleep per night and are associated with an increased risk of hip fractures and pneumonia in elderly patients. 2 Neuroleptic medications may be required for aggression or psychosis in dementia but are typically not effective for wandering behaviors, which are better treated with nonpharmacologic strategies including redirection and safety door locks or alarms. Neuroleptic medications are associated with increased cardiovascular morbidity and mortality and cerebrovascular events in patients with dementia.
